Three things to know:
1. The “plasmabot” asks a series of questions to determine whether users are good candidates to donate plasma. It then directs them to a site where they can safely make a donation.
2. Microsoft collaborated with pharmaceutical companies in this initiative. The FDA has not approved convalescent plasma treatments, but does regulate it, and Microsoft sees the treatment as a worthwhile investment.
3. Microsoft lead researcher Peter Lee said the treatment could save lives, and the company aims to devote computing resources, infrastructure and engineering talent to support it.
More articles on healthcare:
3 ways UW Medicine’s IT team would have responded differently to COVID-19
How Northwell, Mass General and other hospitals are keeping physicians and patients connected
Where IT leaders are spending during the pandemic: 5 things to know
